Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
8:00 AM ET 9/11/24 | GlobeNewswire
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
Contributing Funding and a Significant Additional Tool to Combat PTSD and TBI
JACKSON CENTER, Pa., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB), in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with the Halberd/Athena teams and to fund key advanced research, including the pending FDA IND study utilizing Halberd's LDX technology and Athena Corporation's WatchDawg(TM) monitoring technology.
Defense Atomics Corporation agreed to use its proprietary CRISPR/Nanotechnology Stem Cell treatment for PTSD/TBI in a minimum of 10 paid veterans in a government pilot study of this cutting-edge protocol. Based on Defense Atomics' success using CRISPR methodology with overseas patients, this study is intended to substantiate the benefits of this technology in conjunction with Halberd/Athena's LDX PTSD and TBI/Brain Injury protocol.
"While we have observed statistically compelling results in PTSD/TBI management using CRISPR," says CEO Dr. Gabe Vlad of Defense Atomics Corp., "the ability to significantly integrate our treatment protocols with those of Halberd/Athena's medication and monitoring technologies is quite attractive. The WatchDawg monitoring allows us to acquire near real time (NRT) objective data with respect to the administration of CRISPR. From the preliminary data, there's no question that the LDX formulation adds clear adjunctive relief."
Dr. Mark Darrah, of Athena GTX added: "The early results of WatchDawg in LDX therapy are compelling and show that dovetailing therapies of many different forms with real data in brain health studies may hold the key to FDA clearance." He added, "It is much harder to argue against near real time data as opposed to mere recollections of subjective observations alone."
"We look forward to expanded use of LDX, and now that we can actually see the results documented by the WatchDawg technology in military veterans, the benefit in many modalities is limitless," says CEO of Halberd Corporation, William A. Hartman. Hartman continued, "Having commercial packaging of LDX and potentially CRISPR will allow us to market to physician groups even without formal FDA approval under current compounding laws, particularly with our access to, and relationships with, reputable and qualified compounding facilities. This product is useful for myriad disorders from PTSD, anxiety, depression, anger and addiction, to Chronic Covid, Alzheimer's, Chronic Kidney Disease (CKD), diabetes, and others. It has been shown to be remarkably without side-effects. These benefits are unique and extremely important to a successful endeavor. We now have a large quantity of commercially available product (LDX), enabling our team to aggressively market LDX to physician groups, hospitals, rehab centers...and something we haven't discussed and will expand on shortly, animal hospitals and clinics. This finally gives us great potential for real income and a go-to-market capability with actual product. This cannot at this point go directly to consumers, and must go through physicians, which is a potential market. Until then, the physician will be highly incentivized to utilize LDX, so that's a plus."
"While CRISPR is limited in FDA usage in the United States," ATP's Dr. Richard Goulding explains, "the FDA is looking for well-conceived studies to prove efficacy, particularly in areas where little to no other remedy is offered (Right to Try). LDX alone should be a go-to adjunct to all patients with anxiety and PTSD," says Dr. Goulding, adding, "we welcome the opportunity to clinically verify it."
Dr. Vlad added: "I have analyzed the preliminary data offered by the first tranche of patients from the WatchDawg pilot study, and realized that this is clearly the best fit for further research and justification for our CRISPR technology to be used in PTSD and those suffering brain injury. With WatchDawg, we can prove efficacy, or at least support it, all while demonstrating safety and efficacy from initial therapeutic intervention forward. What's exciting to me is the ability to see, thanks to the WatchDawg monitoring technology, real-time therapeutic effects on the individual. With WatchDawg, we would know immediately when something is working or not working, while quantitatively providing real-time data. That's a game changer. We have recently been awarded significant cash contracts and are thrilled to be able to have the funds to engage in this exciting trial with our new partners. Helping veterans suffering from suicidal ideation and PTSD has always been my fondest wish, especially since I am myself a veteran."
Dr. Vlad reports that "Defense Atomics Corp. successfully engineered specialty proprietary stem cells for this endeavor. Essentially what CRISPR does is to collect and utilize the patient's own blood and performs an extremely unique proprietary gene-editing process combined with stem cells to facilitate their goals. Historical results on patients have been quite compelling. I am committed to funding this study with Halberd/Athena. There are still significant regulatory hurdles to overcome, but we have the right personnel on board now to navigate these hurdles. Obviously, the key is to get the FDA the data and information they need to move this treatment forward. We also want veterans suffering from PTSD to have LDX available to them at low cost, so their medical teams can procure it from our existing charity, Stemofhope.com, since we have a commercial quantity of LDX available and all of the high-tech products utilized in the WatchDawg program monitoring platforms."
How large is the Market?
Databridgemarketresearch.com reports the global market for Post-Traumatic Stress Disorder (PTSD) treatments experienced steady growth. As of 2022
there is 3 prs
if u r a miner let me know
i like ur all opinion on the month u think they will be pulling gold out of the ground to take to the finery just give me the month like 1,2,3,and so on,thank i may do 10 million shares i need to know about when i need the money to do this,thanks i need some help here may help u out 2
yes great process
sorry wrong board
ok its true
that chits is 2yrs old,try the new news
thank u we knew its coming sooner or latter so here it is
sorry i got it at .00035
yes i own 6 million shares cost me a lot but got my 1st million at .0035
check out there other parter halb,its going to be a cash flow to,HALB BIG TIME SO GKARE CHK IT OUT LET ME KNOW WHAT U THINK OF IT
yes i did on the 12th of this month after what to confirm and i knew so i got 1 mil more shares i know it coming big time lots of money will be a cash flow of big money hang on its going to be a long and fast ride so put ur seat belts and drive safe,look luck to everone here even to the bashers u got me the price i needed to buy
had to get annother mil;thank u gkare
yes thanks for reminding me,i am going to buy more
.0014
got my 2 mil.shares
Halberds Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans
8:21 AM ET 4/30/24 | Dow Jones
LDN+ Drug Designed to Combat PTSD and Suicidal Ideation
JACKSON CENTER, PA / ACCESSWIRE / April 30, 2024 / Halberd Corporation (OTC PINK:HALB) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot study demographic of thirty (30) participants, followed by a significantly larger safety study of 150 participants in the coming weeks.
The military has a significant Post Traumatic Stress Disorder (PTSD) and suicide ideation problem and is actively seeking solutions. Halberd's LDN+ drug acts as an antagonist against chemical and alcohol use disorder (AUD) and is uniquely formulated to relieve pain and anxiety associated PTSD and suicidal ideation.
Additional details will be released as the clinical trial progresses. These studies include not only the patented pharmaceutical but 24/7 wearable physiological and psychological monitoring of all participants and the opportunity for each participant to engage in adjunct therapies.
To stay updated on the latest developments from Halberd, subscribe by submitting this form. (https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation
Halberd Corporation (OTC PINK:HALB), a publicly traded entity on the OTC Market, adh
zoom
those 500000 were a buy,me
vol=1,310,70 0
ask=.0092
vol-284,000
NEWS out halb
from the last pr=More news to be issued shortly."
looks like it$$$$$$$$$$$$$$$$$$$$
CORRECTION BY SOURCE: Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
Press Release | 01/10/2024
Correction: The initial release stated Mr. Peter Croden was previously Global President of Upjohn/Pfizer Animal Health Division in Germany. The Animal Health Division is located in Kalamazoo, Michigan. We are sorry for any confusion this may have caused.
Athena will employ its successful history of securing government contracts, spearheading such initiatives
JACKSON CENTER, PA / ACCESSWIRE / January 10, 2024 / Halberd Corporation (OTC-PINK:HALB) is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa, (www.athenagtx.com). Athena GTX is a private enterprise specializing in providing medical care solutions tailored for first responders in both civilian and government sectors.
Athena's 20+ year history of innovative research and development funding from the government (representing 60% of its income historically) in terms of multi-year contracts and grants, and specifically, novel military products and services averaged about $4-5 million per year with substantial growth still ongoing in these markets. This agreement aligns Athena GTX's proven expertise and vast connections with breakthrough Intellectual property owned by Halberd. Together, their 2024 aggressive development plans include rapid release of products into a market Halberd has not been able to tap into for both Halberd's innovative Traumatic Brain Injury (TBI) nasal spray therapy and LDN+ for Post Traumatic Stress Disorder (PTSD), suicidal ideation, pain, anxiety, and drug/alcohol addiction common in returning veterans. This, according to new highly exciting government proposals, suggests an enormously exciting year ahead, particularly with the feedback received from these agencies.
Dr. Mark Darrah, CEO of Athena, stated; "The combination of ongoing University research on Halberd's unique concept products today, with very credible preliminary results, and the enormous market demands we serve, is a natural win-win for both companies. Our plan is to bolster funding in these efforts, capture new research dollars from the government, and push the technology solutions through the FDA and into vertical markets expeditiously. These product solutions dovetail nicely into what we do now and whom we serve. I could not be more pleased!
Recent business analyses detailed our five-year plan forward documenting a compelling market demand and overall an $80 billion potential diversified market expanding at impressive annual growth rates. With Athena's 2024-2026 revenue projections nearly doubling, the Athena partnership with Halberd now represents unparalleled growth projections for both companies."
Peter Croden, Chairman of the Board of CrodenHealth Corp. (another new joint venture partner of Halberd) and former President of Upjohn/Pfizer Canada as well as later Global President of Upjohn/Pfizer Animal Health Division, headquartered in Kalamazoo Michigan, stated, "CrodenHealth Corp. is looking forward to a very successful relationship with Athena GTX and the Halberd Corporation. And, yes, it is going to be a great year in 2024!!."
William A. Hartman, Chairman, President and CEO of Halberd Corporation, added, "Beginning 2023, the task ahead looked daunting- - Halberd needed seven key elements in order to seriously plan for future commercial applications for our technology products, and these were:
Research funding for our base antibody/antigen experimentation at Youngstown State University;
Research funding for our continuing animal testing at Mississippi State University;
Funding for potential clinical trials of our patented LDN+ drug and our patent-pending TBI nasal spray;
Funding for potential FDA certification testing of both products;
Knowledge of how to work with the military and a reputation as a qualified supplier with the purchasing agents at the military agencies;
Experience in launching biomedical products into the market; and
Contacts with Big Pharma for potential future ventures and a potential eventual lucrative buyout.
I can safely say that we have secured all of the desired elements with our newly announced ventures with CrodenHealth Corp and Athena GTX. It has taken many months to put this master plan into form, but we have finally assembled the perfect team. We expect great things to happen rather quickly in 2024 because some of the advanced steps have already been initiated. More news to be issued shortly."
To get the latest
on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Athena GTX, Inc.
Athena GTX is a certified DoD small business with Corporate Headquarters in Johnston, Iowa. Athena focuses development on wearables and highly mobile, wirelessly connected monitoring technologies, and transitioning those to key markets to meet unmet needs of first responders worldwide. Wireless Patient Monitoring - Athena GTX connects patient and provider About - Athena GTX® Inc.
About CrodenHealth Corp
"We help scale amazing companies!"SM
CrodenHealth Corp. is a powerful modern team in healthcare. CrodenHealth Corp ensures clients achieve profitable growth through branding, strategic marketing, & tailored go to market strategies. With an exceptional team of marketing and industry experts, we collaborate with our clients to develop or optimize strategies and support successful implementation while maximizing return on investment (ROI).
See: http://crodenhealth.com/
About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company' cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are
arket Cap Market Cap
5,858,748
01/09/2024
yes it is$$$$$$$$$$$$$
BUSINESS DESCRIPTION,halb
Halberd Corp is a research-based company seeking to develop treatments for a range of diseases. Their extracorporeal method treats blood-borne, neurological and infectious diseases. Halberd's patents remove bodily fluids in a continuous fashion, like dialysis, or in a batch process. To treat the specific disease, the treatment is applied to the bodily fluid extracorporeally, or outside the body. Disease eradication occurs when designed disease-specific antibodies conjoined with metallic nanoparticles come in contact with disease antigens, and the resultant conjoined antibody/nanoparticle/antigen moiety are then exposed to radio frequency, laser irradiation, or chemical bonding and are destroyed. The cleansed bodily fluids are then returned to the patient without deadly side effects associated with injected or ingested medications.Halberd's technology base consists of four issued patents and 22 pending patents: Projects with potential submission to government/military agencies include: * Extracorporeal eradication of inflammatory cytokines from cerebrospinal fluid associated with PTSD and Suicidal Ideation * Therapeutic lozenges to alleviate pain and anxiety as well as chemical and alcohol addiction * Eradication of antibiotic-resistant bacteria and deadly Candida Auris fungi supplied by CDC * Development of a nasal spray is in pre-clinical testing designed to eliminate neurodegenerative cascade associated of head trauma
BUSINESS DESCRIPTION,halb
Halberd Corp is a research-based company seeking to develop treatments for a range of diseases. Their extracorporeal method treats blood-borne, neurological and infectious diseases. Halberd's patents remove bodily fluids in a continuous fashion, like dialysis, or in a batch process. To treat the specific disease, the treatment is applied to the bodily fluid extracorporeally, or outside the body. Disease eradication occurs when designed disease-specific antibodies conjoined with metallic nanoparticles come in contact with disease antigens, and the resultant conjoined antibody/nanoparticle/antigen moiety are then exposed to radio frequency, laser irradiation, or chemical bonding and are destroyed. The cleansed bodily fluids are then returned to the patient without deadly side effects associated with injected or ingested medications.Halberd's technology base consists of four issued patents and 22 pending patents: Projects with potential submission to government/military agencies include: * Extracorporeal eradication of inflammatory cytokines from cerebrospinal fluid associated with PTSD and Suicidal Ideation * Therapeutic lozenges to alleviate pain and anxiety as well as chemical and alcohol addiction * Eradication of antibiotic-resistant bacteria and deadly Candida Auris fungi supplied by CDC * Development of a nasal spray is in pre-clinical testing designed to eliminate neurodegenerative cascade associated of head trauma
lb.
BUSINESS DESCRIPTION
Halberd Corp is a research-based company seeking to develop treatments for a range of diseases. Their extracorporeal method treats blood-borne, neurological and infectious diseases. Halberd's patents remove bodily fluids in a continuous fashion, like dialysis, or in a batch process. To treat the specific disease, the treatment is applied to the bodily fluid extracorporeally, or outside the body. Disease eradication occurs when designed disease-specific antibodies conjoined with metallic nanoparticles come in contact with disease antigens, and the resultant conjoined antibody/nanoparticle/antigen moiety are then exposed to radio frequency, laser irradiation, or chemical bonding and are destroyed. The cleansed bodily fluids are then returned to the patient without deadly side effects associated with injected or ingested medications.Halberd's technology base consists of four issued patents and 22 pending patents: Projects with potential submission to government/military agencies include: * Extracorporeal eradication of inflammatory cytokines from cerebrospinal fluid associated with PTSD and Suicidal Ideation * Therapeutic lozenges to alleviate pain and anxiety as well as chemical and alcohol addiction * Eradication of antibiotic-resistant bacteria and deadly Candida Auris fungi supplied by CDC * Development of a nasal spray is in pre-clinical testing designed to eliminate neurodegenerative cascade associated of head trauma
OTC DISCLOSURE & NEWS SERVICE
Halberd Corporation Signs Multi-Faceted Agreement with CrodenHealth.com
Press Release | 12/13/2023
Peter Croden, CrodenHealth Chairman, previously executive with Pharmacia & Upjohn (Pfizer), Upjohn Canada, Upjohn Global Animal Health, NephRx, and Parnell Pharmaceuticals Holdings, Ltd. Endeavors to move Halberd forward
JACKSON CENTER, PA / ACCESSWIRE / December 13, 2023 / Halberd Corporation (OTC PINK:HALB) and CrodenHealth.com of Canada agree to produce, market, sell and distribute Halberd's patented low dose naltrexone combo product(s) worldwide. The agreement also allows CrodenHealth.com right of first refusal regarding similar rights to future products in Halberd's development pipeline.
Peter Croden, Chairman of the Board of CrodenHealth, enjoys a long history in the pharmaceutical industry- over 30 years with Upjohn & Pharmacia Corp. (now Pfizer) in various senior management roles, including President and General Manager of Upjohn Canada and later, President Upjohn Worldwide Animal Health. In 2001, Mr. Croden launched the biotechnology company, NephRx as CEO. In 2015, Mr Croden was appointed to the Board of Parnell Pharmaceuticals Holdings, Ltd.
Peter Croden, together with his son, Brad Croden, and nephew, Todd Croden, have over five decades of experience in the pharmaceuticals industry, culminating in the management of CrodenHealth.com. CrodenHealth's role with Halberd Corporation will include efforts to facilitate industry joint ventures and funding as well as drug certification efforts.
Brad Croden, CEO of CrodenHealth, commented, "We are excited to monetize the amazing current & future intellectual property (products) of Halberd Corporation; creating new & profitable revenue streams. This new agreement marks the beginning of a long fruitful win-win relationship between CrodenHealth & Halberd Corporation."
Peter Croden added, "With CrodenHealth's vast pharmaceutical sales & marketing expertise and Halberd Corporations unique groundbreaking intellectual property & first-to-market products - will ensure a profitable positive impact on patient outcomes."
William A. Hartman, Chairman, President, and CEO of Halberd Corporation, commented, "Given the commitment of CrodenHealth, coupled with the principals' vast network of relationships and past dealings with large pharmaceutical companies, they have the wherewithal to facilitate game changing joint ventures. These relationships, should also inure to the benefit of Athena GTX and complements many of Halberd's other efforts in the medical field. They also enhance Halberd's capacity to fulfill its commitments to the various military organizations which have specifically expressed interest in one or more of Halberd's endeavors. CrodenHealth also has access to unique applications of bio-marker artificial intelligence in various medical applications."
To stay updated on the latest developments from Halberd, subscribe by submitting this form. (https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter: @HalberdC
About CrodenHealth.com
"We help scale amazing companies!"SM
CrodenHealth is a powerful modern team in healthcare. CrodenHealth ensures clients achieve profitable growth through branding, strategic marketing, & tailored go to market strategies. With an exceptional team of marketing and industry experts, we collaborate with our clients to develop or optimize strategies and support successful implementation while maximizing return on investment (ROI).
See: http://crodenhealth.com/
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), a publicly traded entity on the OTC Market, adheres fully to OTC Market reporting regulations. Following its restructuring in April 2020, Halberd secured exclusive global rights to three granted patents and submitted 22 associated provisional, PCT, or utility patent
Hheres something about batteriesOTC DISCLOSURE & NEWS SERVICE
Premier Biomedical Inc. (OTC-PINK: “BIEI“), now known as Premier Graphene, Inc., collaborates with Oklahoma Based “Biographene Technology Inc”, for its Graphene Production.
Press Release | 03/16/2023
Premier Biomedical Inc. (OTC-PINK: "BIEI"), now known as Premier Graphene, Inc., collaborates with Oklahoma Based "Biographene Technology Inc", for its Graphene Production.
These graphene products, manufactured by Biographene Technology, its proprietary Multi-wall Carbon Nanotubes (MWCNTs) sourced from Hemp Fiber for a high-grade production capacity of five tons per week of graphene.
March 16, 2023 Premier Biomedical Inc., now known as Premier Graphene, Inc. (OTC-PINK: BIEI), relocating to Imperial Valley CA, announces its acquisition of a partial ownership in Oklahoma Based Biographene Technology Inc, https://www.biographenetechnologyinc.com/. An innovativeleader in the bio graphene industry, headed by its chief scientist, Michael McDonnough.
Premier Graphene Inc focuses on cost-effective, green technology of scientific applications, including hemp-basedgraphene enhanced formulations for a myriad of biomedical, commercial and military applications. These applications include: concrete, asphalt, 3D printing filaments, ballistic armor, UHMW polyethylene, an anti-viral / anti-bacterial multi-surface coating, fireproof polyurethane insulation expansion foams, anti-abrasion coatings, and neat & recycled PET, HDPE, and other polymers. Its partner in pursuit of these applications is Oklahoma Based Biographene Technology Inc. After weeks of due diligence and negotiation, we have reached an agreementreports Premier Graphene Inc senior consultant Pedro Mendezand brother of CEO Ivan Mendez.
Ivan Mendez CEO of Premier Graphene Inc. explains Premier Graphene and its officers and directors welcomeBiographeneTechnology Inc.s CEO, Adam Havig and its chief scientist in charge of product development, Michael McDonnough to our family. With them on board, we have most of the pieces needed for the most technical part of graphene production in North America. Separately, Premier Graphene, Inc. will be securing the raw materials, hemp, for the high-grade production of graphene. I believe that this association will provide us with yet another critical piece that we can employ for a successful endeavor in this burgeoning, incredibly efficacious arena.
Adam Havig, CEO of Biographene Technology Inc., added, We are excited to partner with the Premier Graphene Inc. With this agreement, we can further meet our goals as becoming one of the industrys premier leaders in the graphene and bio-graphite replacement market. Within the next year, we expect our production facility to be able to produce up to 15,000 tons per year.
Premier Graphene Incs production program will be an eco-friendly, sustainable and cost-effective process. They are designed to be bio-enhanced/bio-beneficial (more than just eco-friendly but carbon negative) products. Such products will include graphene-enhanced concrete, superconductive graphene products and electric batteries with enhanced capacity. They will also be lightweight in order to achieve certain unparalleled benefits, including for electric vehicles, aerospace, military and other commercial applications. Epidemiologic Solutions Corporation, a public charity, is donating $150,000, for no consideration. This will enable Premier Graphene to own 10% of Biographene Technology. More importantly, however, it will enable both to acquire, used equipment and repurpose it at a collective cost of approximately 10% of the cost if acquired unused. We will be able to acquire low cost, but highly suitable hemp as the raw material for a high-grade and highly efficacious, most suitable form of graphene possible. Ultimately, with this talented scientific team we are confident that these strategies will result in high quality, highly innovative, products at a more reasonable price in this highly competitive market.
OTC DISCLOSURE & NEWS SERVICE
Premier Biomedical Inc. (OTC-PINK: “BIEI“), now known as Premier Graphene, Inc., collaborates with Oklahoma Based “Biographene Technology Inc”, for its Graphene Production.
Press Release | 03/16/2023
Premier Biomedical Inc. (OTC-PINK: "BIEI"), now known as Premier Graphene, Inc., collaborates with Oklahoma Based "Biographene Technology Inc", for its Graphene Production.
These graphene products, manufactured by Biographene Technology, its proprietary Multi-wall Carbon Nanotubes (MWCNTs) sourced from Hemp Fiber for a high-grade production capacity of five tons per week of graphene.
March 16, 2023 Premier Biomedical Inc., now known as Premier Graphene, Inc. (OTC-PINK: BIEI), relocating to Imperial Valley CA, announces its acquisition of a partial ownership in Oklahoma Based Biographene Technology Inc, https://www.biographenetechnologyinc.com/. An innovativeleader in the bio graphene industry, headed by its chief scientist, Michael McDonnough.
Premier Graphene Inc focuses on cost-effective, green technology of scientific applications, including hemp-basedgraphene enhanced formulations for a myriad of biomedical, commercial and military applications. These applications include: concrete, asphalt, 3D printing filaments, ballistic armor, UHMW polyethylene, an anti-viral / anti-bacterial multi-surface coating, fireproof polyurethane insulation expansion foams, anti-abrasion coatings, and neat & recycled PET, HDPE, and other polymers. Its partner in pursuit of these applications is Oklahoma Based Biographene Technology Inc. After weeks of due diligence and negotiation, we have reached an agreementreports Premier Graphene Inc senior consultant Pedro Mendezand brother of CEO Ivan Mendez.
Ivan Mendez CEO of Premier Graphene Inc. explains Premier Graphene and its officers and directors welcomeBiographeneTechnology Inc.s CEO, Adam Havig and its chief scientist in charge of product development, Michael McDonnough to our family. With them on board, we have most of the pieces needed for the most technical part of graphene production in North America. Separately, Premier Graphene, Inc. will be securing the raw materials, hemp, for the high-grade production of graphene. I believe that this association will provide us with yet another critical piece that we can employ for a successful endeavor in this burgeoning, incredibly efficacious arena.
Adam Havig, CEO of Biographene Technology Inc., added, We are excited to partner with the Premier Graphene Inc. With this agreement, we can further meet our goals as becoming one of the industrys premier leaders in the graphene and bio-graphite replacement market. Within the next year, we expect our production facility to be able to produce up to 15,000 tons per year.
Premier Graphene Incs production program will be an eco-friendly, sustainable and cost-effective process. They are designed to be bio-enhanced/bio-beneficial (more than just eco-friendly but carbon negative) products. Such products will include graphene-enhanced concrete, superconductive graphene products and electric batteries with enhanced capacity. They will also be lightweight in order to achieve certain unparalleled benefits, including for electric vehicles, aerospace, military and other commercial applications. Epidemiologic Solutions Corporation, a public charity, is donating $150,000, for no consideration. This will enable Premier Graphene to own 10% of Biographene Technology. More importantly, however, it will enable both to acquire, used equipment and repurpose it at a collective cost of approximately 10% of the cost if acquired unused. We will be able to acquire low cost, but highly suitable hemp as the raw material for a high-grade and highly efficacious, most suitable form of graphene possible. Ultimately, with this talented scientific team we are confident that these strategies will result in high quality, highly innovative, products at a more reasonable price in this highly competitive market.
1 agree, got me 300000 more,i dont think there r many shares available out there,will see
i have some shares,how do i sell,give me a web-site,thank u i am new to this got some free shares about 2 yrs ago,i am completely loss here
i have some shares,how do i sell,give me a web-site,thank u i am new to this got some free shares about 2 yrs ago,i am completely loss here
how do i sell bitcoin
i didnt say when now did i,but one thing u can count on its coming so u better buy some before its to late
$HALB Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts
https://www.accesswire.com/785790/halberd-and-athena-gtx-collaborate-on-advanced-traumatic-brain-injury-tbi-monitoring-and-applications-for-government-contracts
HALB Quote
Detailed Quote Discussion Board
Logo for quote
HALB
Halberd Corp (PK)
0.011
0.0015 (15.79%)
Volume